Global Wealth Management Investment Advisory Inc. Has $1.37 Million Position in Novo Nordisk A/S (NYSE:NVO)

Global Wealth Management Investment Advisory Inc. grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,499 shares of the company’s stock after acquiring an additional 441 shares during the quarter. Global Wealth Management Investment Advisory Inc.’s holdings in Novo Nordisk A/S were worth $1,369,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. 1620 Investment Advisors Inc. bought a new stake in Novo Nordisk A/S during the second quarter worth $25,000. Strategic Investment Solutions Inc. IL purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Orion Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S during the first quarter worth $26,000. Gilliland Jeter Wealth Management LLC grew its holdings in Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares in the last quarter. Finally, Halpern Financial Inc. increased its holdings in Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $1.38 during trading hours on Tuesday, reaching $108.34. 572,802 shares of the stock traded hands, compared to its average volume of 4,355,628. The company’s 50-day simple moving average is $123.74 and its two-hundred day simple moving average is $130.85. The company has a market capitalization of $486.18 billion, a P/E ratio of 37.58, a price-to-earnings-growth ratio of 1.46 and a beta of 0.42. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Equities research analysts forecast that Novo Nordisk A/S will post 3.01 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.